NCT03513666View on ClinicalTrials.gov

A Study of Toripalimab+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 9, 2018

Primary Completion Date

August 12, 2022

Study Completion Date

August 12, 2022

Conditions
NSCLC
Interventions
COMBINATION_PRODUCT

Drug intervention

anti-PD-1 monoclonal antibody Toripalimab injection combined with Pemetrexed and carboplatin

Trial Locations (5)

210029

Jiangsu Province Hospital, Nanjing

310003

The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou

310022

Zhengjiang Cancer Hospital, Hangzhou

Unknown

Shanghai Pulmonary Hospita, Shanghai

Tangdu Hospital, Xi’an

All Listed Sponsors
lead

Shanghai Junshi Bioscience Co., Ltd.

OTHER

NCT03513666 - A Study of Toripalimab+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI Treatment | Biotech Hunter | Biotech Hunter